Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644
This examiner grants 38% of resolved cases
Dennis Cherian George examines cases in Tech Center 1600 and Art Unit 1644. With 13 resolved cases, the examiner has an allowance rate of 38.5%, showing a challenging environment for applicants. This low rate indicates that more than half of the applications do not reach a grant, requiring practitioners to be well-prepared for potential rejections.
The interview lift is 72.7%, which is an exceptionally high figure. This indicates that interviews are an incredibly powerful tool for applicants to use when working with this examiner, as they dramatically increase the chances of success. The massive lift suggests that oral advocacy is far more effective than written correspondence alone in this examiner's practice.
The median days to allowance is 1308. This timeline indicates a standard prosecution duration for the tech center, requiring over three years to reach a final resolution. The combination of a low allowance rate and an extremely high interview lift suggests that while the process is difficult, oral advocacy is the most critical strategy for success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17416859 | T-CELL RECEPTOR MODIFIED OBJECT | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17405613 | COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY | Final Rejection | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17627385 | ANTIBODY COMBINATIONS FOR TREATMENT OF CANCER IN SPECIFIC PATIENTS | Final Rejection | UNIVERSITY OF SOUTHAMPTON |
| 17915761 | IMMUNOMODULATORY COMPOSTIONS AND USE THEREOF | Non-Final OA | BIOND BIOLOGICS LTD. |
| 18335542 | USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6 | Final Rejection | Biocon Limited |
| 17368346 | IL-12 COMPOSITIONS AND METHODS OF USE IN HEMATOPOIETIC RECOVERY | Non-Final OA | Karyopharm Therapeutics Inc. |
| 17909045 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | Non-Final OA | GO Therapeutics, Inc. |
| 17442461 | PROTEINACEOUS HETERODIMER AND USE THEREOF | Final Rejection | SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD. |
| 17792566 | METHOD FOR SEPARATION OF SPERM WITH UNDAMAGED INTACT HEADS FROM SPERM WITH DAMAGED HEADS AND SOMATIC CELLS | Final Rejection | CESKA ZEMEDELSKA UNIVERZITA V PRAZE |
| 17784489 | SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF | Non-Final OA | Legend Biotech USA Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy